Similar Items: CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing
- Years of Life Lost of Patients With Early Adenocarcinoma of the Esophagogastric Junction Compared to Esophageal or Gastric Adenocarcinoma. A Registry‐Based Study
- Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
- Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma
- Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
- From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics
- Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma